

George G Netto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9055835/publications.pdf>

Version: 2024-02-01

286
papers

20,980
citations

15504

65
h-index

12597

132
g-index

301
all docs

301
docs citations

301
times ranked

27057
citing authors

#	ARTICLE	IF	CITATIONS
1	Spindle Cell Sarcoma of the Uterus Harboring <i>MEIS1::NCOA1</i> Fusion Gene and Mimicking Endometrial Stromal Sarcoma. <i>International Journal of Surgical Pathology</i> , 2023, 31, 227-232.	0.8	1
2	TSC loss is a clonal event in eosinophilic solid and cystic renal cell carcinoma: a multiregional tumor sampling study. <i>Modern Pathology</i> , 2022, 35, 376-385.	5.5	19
3	Programmed cell death ligand 1 expression in different molecular subtypes of upper tract urothelial carcinoma. <i>International Journal of Urology</i> , 2022, 29, 89-90.	1.0	3
4	BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer. <i>Journal of Pathology</i> , 2022, 256, 223-234.	4.5	9
5	GPNMB expression identifies TSC1/2/mTOR-associated and MIT family translocation-driven renal neoplasms. <i>Journal of Pathology</i> , 2022, 257, 158-171.	4.5	21
6	UALCAN: An update to the integrated cancer data analysis platform. <i>Neoplasia</i> , 2022, 25, 18-27.	5.3	666
7	High-fat diet promotes prostate cancer growth through histamine signaling. <i>International Journal of Cancer</i> , 2022, 151, 623-636.	5.1	12
8	Meta-analysis of the robustness of COVID-19 diagnostic kit performance during the early pandemic. <i>BMJ Open</i> , 2022, 12, e053912.	1.9	1
9	An introduction to the WHO 5th edition 2022 classification of testicular tumours. <i>Histopathology</i> , 2022, 81, 459-466.	2.9	32
10	WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. <i>Histopathology</i> , 2022, 81, 426-438.	2.9	39
11	The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. <i>European Urology</i> , 2022, 82, 458-468.	1.9	212
12	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 461-493.	2.5	143
13	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 295.e1-295.e8.	1.6	6
14	Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2021, 79, 364-371.	1.9	41
15	Well-differentiated neuroendocrine tumors of the lower urinary tract: biologic behavior of a rare entity. <i>Human Pathology</i> , 2021, 109, 53-58.	2.0	5
16	TFEB rearranged renal cell carcinoma. A clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1. <i>Modern Pathology</i> , 2021, 34, 842-850.	5.5	26
17	Identification of BXDC2 as a Key Downstream Effector of the Androgen Receptor in Modulating Cisplatin Sensitivity in Bladder Cancer. <i>Cancers</i> , 2021, 13, 975.	3.7	11
18	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1167-1184.	5.5	118

#	ARTICLE	IF	CITATIONS
19	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 134-143.	4.9	299
20	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1392-1424.	5.5	138
21	Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from cross-sectional data. International Journal of Urology, 2021, 28, 774-776.	1.0	5
22	Gut Microbiotaâ€œDerived Short-Chain Fatty Acids Promote Prostate Cancer Growth via IGF1 Signaling. Cancer Research, 2021, 81, 4014-4026.	0.9	83
23	Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8+ Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 680973.	4.8	20
24	Diagnostic utility of one-stop fusion gene panel to detect TFE3/TFEB gene rearrangement and amplification in renal cell carcinomas. Modern Pathology, 2021, 34, 2055-2063.	5.5	14
25	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Advances in Anatomic Pathology, 2021, 28, 196-208.	4.3	20
26	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. Advances in Anatomic Pathology, 2021, 28, 179-195.	4.3	23
27	Clinical Application of TERT Promoter Mutations in Urothelial Carcinoma. Frontiers in Oncology, 2021, 11, 705440.	2.8	12
28	Molecular Pathology of Urothelial Carcinoma. Surgical Pathology Clinics, 2021, 14, 403-414.	1.7	4
29	Testicular Germ-Cell Tumors with Spermatic Cord Involvement: A Retrospective International Multi-Institutional Experience. Modern Pathology, 2021, , .	5.5	4
30	Androgen Receptor Signaling Induces Cisplatin Resistance via Down-Regulating GULP1 Expression in Bladder Cancer. International Journal of Molecular Sciences, 2021, 22, 10030.	4.1	12
31	Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey. Journal of Clinical Pathology, 2021, 74, 291-299.	2.0	14
32	Vascular architectural patterns in clear cell renal cell carcinoma and clear cell papillary renal cell carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 1187-1196.	2.8	4
33	Molecular Biomarker Testing in Localized Prostate Cancer: The Critical Role of Pathologists. Archives of Pathology and Laboratory Medicine, 2021, 145, 264-265.	2.5	1
34	Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. American Journal of Cancer Research, 2021, 11, 3990-4001.	1.4	4
35	Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 423-429.	2.8	30
36	Tumour immune microenvironment in primary and metastatic papillary renal cell carcinoma. Histopathology, 2020, 76, 423-432.	2.9	11

#	ARTICLE	IF	CITATIONS
37	Updates on the Genomics of Bladder Cancer and Novel Molecular Taxonomy. <i>Advances in Anatomic Pathology</i> , 2020, 27, 36-43.	4.3	20
38	The Ever Changing Landscape of Anatomic Pathology Practice. <i>Advances in Anatomic Pathology</i> , 2020, 27, 1-2.	4.3	2
39	Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate. <i>American Journal of Surgical Pathology</i> , 2020, 44, 673-680.	3.7	31
40	Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5390.	4.1	48
41	GULP1 regulates the NRF2-KEAP1 signaling axis in urothelial carcinoma. <i>Science Signaling</i> , 2020, 13, .	3.6	19
42	Rare MDM2 amplification in a fat-predominant angiomyolipoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 661-666.	2.8	1
43	Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 755.	2.8	25
44	Acute kidney injury promotes development of papillary renal cell adenoma and carcinoma from renal progenitor cells. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	46
45	Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 93-102.	2.8	15
46	Editorial. <i>Modern Pathology</i> , 2020, 33, 178-178.	5.5	0
47	Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression. <i>Oncogene</i> , 2020, 39, 4077-4091.	5.9	19
48	FOXO1 as a tumor suppressor inactivated via AR/ER β signals in urothelial cells. <i>Endocrine-Related Cancer</i> , 2020, 27, 231-244.	3.1	23
49	Genitourinary Tumors. , 2020, , 133-147.		0
50	Editorial Comment: A modified clinicopathological tumor staging system for survival prediction of patients with penile cancer. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2020, 46, 275-276.	1.5	0
51	The role of adipocytokines and their receptors in bladder cancer: expression of adiponectin or leptin is an independent prognosticator. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 3033-3045.	0.0	4
52	Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder Cancer. <i>Translational Oncology</i> , 2019, 12, 1416-1424.	3.7	21
53	Characterization of glycineâ€œN</i>â€œacyltransferase like 1 (GLYATL1) in prostate cancer. <i>Prostate</i> , 2019, 79, 1629-1639.	2.3	12
54	Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 349-356.	2.8	33

#	ARTICLE	IF	CITATIONS
55	PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays. <i>Human Pathology</i> , 2019, 90, 54-59.	2.0	23
56	Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder. <i>Human Pathology</i> , 2019, 89, 24-32.	2.0	20
57	Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma. <i>Modern Pathology</i> , 2019, 32, 1544-1550.	5.5	45
58	Clinical implication of the mammalian target of rapamycin pathway in upper tract urothelial carcinoma with negative GATA binding protein-3 expression. <i>International Journal of Urology</i> , 2019, 26, 678-679.	1.0	2
59	Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma. <i>Cancer Science</i> , 2019, 110, 1771-1779.	3.9	63
60	p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. <i>Cancer Cell</i> , 2019, 35, 204-220.e9.	16.8	62
61	Rare case of squamous cell carcinoma arising from tunica vaginalis in a background of chronic hydrocele. <i>Urology Case Reports</i> , 2019, 23, 55-57.	0.3	1
62	Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. <i>Human Pathology</i> , 2019, 85, 1-9.	2.0	28
63	Insulin-like growth factor-1 receptor expression in upper tract urothelial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 21-27.	2.8	12
64	Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay. <i>Cancer Cytopathology</i> , 2019, 127, 52-61.	2.4	49
65	INSL3 Expression in Leydig Cell Hyperplasia and Leydig Cell Tumors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 203-209.	1.2	11
66	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 479-505.	4.9	943
67	Single 15-Min Protocol Yields the Same Cryoablation Size and Margin as the Conventional 10-10-Min Protocol: Results of Kidney and Liver Swine Experiment. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 1089-1094.	2.0	3
68	Reduced immunohistochemical PTEN staining is associated with higher progression rate and recurrence episodes in non-invasive low-grade papillary urothelial carcinoma of the bladder. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 969-974.	2.8	3
69	Iatrogenic pathology of the urinary bladder. <i>Seminars in Diagnostic Pathology</i> , 2018, 35, 218-227.	1.5	15
70	Nuclear Factor- κ B Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1303-1314.	4.1	33
71	Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. <i>American Journal of Pathology</i> , 2018, 188, 1478-1485.	3.8	119
72	miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. <i>Molecular Cancer Research</i> , 2018, 16, 1125-1137.	3.4	51

#	ARTICLE	IF	CITATIONS
73	Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. <i>Seminars in Cancer Biology</i> , 2018, 52, 216-227.	9.6	14
74	Re-evaluation of 33 "unclassified" eosinophilic renal cell carcinomas in young patients. <i>Histopathology</i> , 2018, 72, 588-600.	2.9	92
75	YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells. <i>Cancer Research</i> , 2018, 78, 168-181.	0.9	77
76	Prostaglandin receptors induce urothelial tumorigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression. <i>British Journal of Cancer</i> , 2018, 118, 213-223.	6.4	35
77	Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1166-1181.	3.7	98
78	Hypomethylation, endogenous retrovirus expression, and interferon signaling in testicular germ cell tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8580-E8582.	7.1	13
79	PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1113-1120.	1.1	135
80	High-Fat Diet-Induced Inflammation Accelerates Prostate Cancer Growth via IL6 Signaling. <i>Clinical Cancer Research</i> , 2018, 24, 4309-4318.	7.0	105
81	Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. <i>ELife</i> , 2018, 7, .	6.0	118
82	Wnt receptor Frizzled 8 is a target of ERG in prostate cancer. <i>Prostate</i> , 2018, 78, 1311-1320.	2.3	25
83	A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression. <i>Neoplasia</i> , 2018, 20, 894-904.	5.3	50
84	PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1384-1389.	3.7	77
85	ATF2 promotes urothelial cancer outgrowth via cooperation with androgen receptor signaling. <i>Endocrine Connections</i> , 2018, 7, 1397-1408.	1.9	24
86	PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263. <i>Oncotarget</i> , 2018, 9, 30465-30471.	1.8	26
87	Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer. <i>Urology</i> , 2017, 102, 148-158.	1.0	12
88	Toward personalized management in bladder cancer: the promise of novel molecular taxonomy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 271-280.	2.8	15
89	MicroRNA expression profiling of Xp11 renal cell carcinoma. <i>Human Pathology</i> , 2017, 67, 18-29.	2.0	25
90	GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator. <i>Human Pathology</i> , 2017, 64, 83-90.	2.0	46

#	ARTICLE	IF	CITATIONS
91	Strong association of insulin-like growth factor 1 receptor expression with histologic grade, subtype, and HPV status in penile squamous cell carcinomas: a tissue microarray study of 112 cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 695-701.	2.8	5
92	Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4693-4703.	7.0	62
93	Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer. <i>Cancer Immunology Research</i> , 2017, 5, 594-603.	3.4	54
94	Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 761-767.	2.8	29
95	Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 475-484.	2.8	16
96	A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157. <i>Clinical Cancer Research</i> , 2017, 23, 3003-3011.	7.0	59
97	MicroRNAs, promising biomarkers in the diagnosis of Xp11 translocation RCC—reply. <i>Human Pathology</i> , 2017, 68, 206-207.	2.0	0
98	Prostate Cancer: An Update on Molecular Pathology with Clinical Implications. <i>European Urology Supplements</i> , 2017, 16, 253-271.	0.1	2
99	Pathology Imagebase—a reference image database for standardization of pathology. <i>Histopathology</i> , 2017, 71, 677-685.	2.9	19
100	AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination. <i>Nature Communications</i> , 2017, 8, 142.	12.8	36
101	Preparing pathology for the molecular era. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 137-140.	2.8	1
102	Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort. <i>Human Pathology</i> , 2017, 59, 55-61.	2.0	58
103	Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 34.e17-34.e25.	1.6	21
104	Urological cancer related to familial syndromes. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2017, 43, 192-201.	1.5	10
105	Lymph node density predicts recurrence and death after inguinal lymph node dissection for penile cancer. <i>Investigative and Clinical Urology</i> , 2017, 58, 20.	2.0	17
106	PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. <i>Oncotarget</i> , 2017, 8, 90123-90131.	1.8	89
107	Characterization of urinary extracellular vesicle proteins in muscle-invasive bladder cancer. <i>Oncotarget</i> , 2017, 8, 91199-91208.	1.8	51
108	ZKSCAN3 promotes bladder cancer cell proliferation, migration, and invasion. <i>Oncotarget</i> , 2016, 7, 53599-53610.	1.8	26

#	ARTICLE	IF	CITATIONS
109	Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. <i>BioMed Research International</i> , 2016, 2016, 1-12.	1.9	19
110	Global 5-Hydroxymethylcytosine Levels Are Profoundly Reduced in Multiple Genitourinary Malignancies. <i>PLoS ONE</i> , 2016, 11, e0146302.	2.5	27
111	Frequent BRAF V600E Mutations in Metanephric Stromal Tumor. <i>American Journal of Surgical Pathology</i> , 2016, 40, 719-722.	3.7	34
112	Extent of renal vein invasion influences prognosis in patients with renal cell carcinoma. <i>BJU International</i> , 2016, 118, 112-117.	2.5	24
113	TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers. <i>American Journal of Surgical Pathology</i> , 2016, 40, 723-737.	3.7	168
114	Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using next-generation sequencing. <i>Cancer Cytopathology</i> , 2016, 124, 744-753.	2.4	31
115	The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. <i>Oncolmmunology</i> , 2016, 5, e1134412.	4.6	135
116	Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e515-e520.	1.9	19
117	Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2016, 23, 2715-2722.	1.5	34
118	The utility of STAT6 and ALDH1 expression in the differential diagnosis of solitary fibrous tumor versus prostate-specific stromal neoplasms. <i>Human Pathology</i> , 2016, 54, 184-188.	2.0	31
119	High-resolution telomere fluorescence in situ hybridization reveals intriguing anomalies in germ cell tumors. <i>Human Pathology</i> , 2016, 54, 106-112.	2.0	8
120	High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 427-434.	2.8	38
121	Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract. <i>Cancer Biology and Therapy</i> , 2016, 17, 1188-1196.	3.4	40
122	Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 408-436.	329.8	33
123	The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2016, 4, 726-733.	3.4	133
124	TFEB-amplified Renal Cell Carcinomas. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1484-1495.	3.7	109
125	Cyclosporine A and tacrolimus inhibit urothelial tumorigenesis. <i>Molecular Carcinogenesis</i> , 2016, 55, 161-169.	2.7	27
126	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. <i>Histopathology</i> , 2016, 69, 441-449.	2.9	82

#	ARTICLE	IF	CITATIONS
127	For staining of ALK protein, the novel D5F3 antibody demonstrates superior overall performance in terms of intensity and extent of staining in comparison to the currently used ALK1 antibody. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 345-350.	2.8	26
128	Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens. <i>American Journal of Clinical Pathology</i> , 2016, 145, 696-702.	0.7	22
129	Overexpression of Insulin-like Growth Factor-1 Receptor Is Associated With Penile Cancer Progression. <i>Urology</i> , 2016, 92, 51-56.	1.0	9
130	Significance of a minor high-grade component in a low-grade noninvasive papillary urothelial carcinoma of bladder. <i>Human Pathology</i> , 2016, 47, 20-25.	2.0	39
131	Role for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma. <i>Lancet, The</i> , 2016, 387, 1881-1882.	13.7	8
132	Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. <i>Human Pathology</i> , 2016, 53, 8-13.	2.0	31
133	High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder. <i>Modern Pathology</i> , 2016, 29, 511-515.	5.5	34
134	A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2016, 195, 880-885.	0.4	22
135	Emerging Bladder Cancer Biomarkers and Targets of Therapy. <i>Urologic Clinics of North America</i> , 2016, 43, 63-76.	1.8	21
136	Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 448-458.	7.0	29
137	Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. <i>European Urology</i> , 2016, 69, 157-165.	1.9	206
138	A Right Atrial Mass: "More Than Meets the Eye". <i>Journal of Clinical Oncology</i> , 2016, 34, e49-e50.	1.6	1
139	Clinical, pathologic, and genomic profiles of exceptional responders to anti-PD1 therapy in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 625-625.	1.6	9
140	Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy. <i>PLoS ONE</i> , 2016, 11, e0146189.	2.5	13
141	Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression: Hoosier Cancer Research Network GU12-157.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4526-4526.	1.6	3
142	PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas. <i>Prostate</i> , 2015, 75, 1610-1619.	2.3	35
143	Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0131245.	2.5	42
144	Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1. <i>Oncotarget</i> , 2015, 6, 1582-1593.	1.8	52

#	ARTICLE	IF	CITATIONS
145	Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use. <i>Cancer Prevention Research</i> , 2015, 8, 208-221.	1.5	51
146	Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 204.e1-204.e7.	1.6	34
147	Assessment of Tumoral PD-L1 Expression and Intratumoral CD8+ TÂCells in Urothelial Carcinoma. <i>Urology</i> , 2015, 85, 703.e1-703.e6.	1.0	122
148	Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases. <i>Human Pathology</i> , 2015, 46, 761-766.	2.0	10
149	Human papillomavirus infection and immunohistochemical p16INK4a expression as predictors of outcome in penile squamous cell carcinomas. <i>Human Pathology</i> , 2015, 46, 532-540.	2.0	43
150	GATA-3 Expression in Trophoblastic Tissues. <i>American Journal of Surgical Pathology</i> , 2015, 39, 101-108.	3.7	80
151	Primary Renal Sclerosing Epithelioid Fibrosarcoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 365-373.	3.7	43
152	Smooth muscle and adenoma-like renal tumor: a previously unreported variant of mixed epithelial stromal tumor or a distinctive renal neoplasm?. <i>Human Pathology</i> , 2015, 46, 894-905.	2.0	7
153	Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. <i>Clinical Cancer Research</i> , 2015, 21, 5619-5629.	7.0	56
154	Cyclin A1 expression predicts progression in pT1 urothelial carcinoma of bladder: a tissue microarray study of 149 patients treated by transurethral resection. <i>Histopathology</i> , 2015, 66, 262-269.	2.9	15
155	¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1003-1010.	5.0	180
156	Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression. <i>Cancer Research</i> , 2015, 75, 4322-4334.	0.9	23
157	Molecular Updates in Prostate Cancer. <i>Surgical Pathology Clinics</i> , 2015, 8, 561-580.	1.7	7
158	Renal carcinoma associated with a novel succinate dehydrogenase A mutation: a case report and review of literature of a rare subtype of renal carcinoma. <i>Human Pathology</i> , 2015, 46, 1951-1955.	2.0	39
159	Utility of uroplakin II expression as a marker of urothelial carcinoma. <i>Human Pathology</i> , 2015, 46, 58-64.	2.0	43
160	Grade Heterogeneity in Small Renal Masses: Potential Implications for Renal Mass Biopsy. <i>Journal of Urology</i> , 2015, 193, 36-40.	0.4	105
161	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. <i>Modern Pathology</i> , 2015, 28, 612-630.	5.5	106
162	Tissue-based genomics to augment post-prostatectomy risk stratification in a natural history cohort.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5059-5059.	1.6	2

#	ARTICLE	IF	CITATIONS
163	PDL1 status in muscle-invasive urothelial carcinoma in the context of neoadjuvant cisplatin-based chemotherapy.. Journal of Clinical Oncology, 2015, 33, 300-300.	1.6	1
164	Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes.. Journal of Clinical Oncology, 2015, 33, 336-336.	1.6	3
165	ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression. Oncotarget, 2015, 6, 29860-29876.	1.8	83
166	Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. Oncotarget, 2015, 6, 39088-39097.	1.8	67
167	Validation of the Decipher prostate cancer classifier in intermediate to high-risk men treated with radical prostatectomy but without additional therapy upon PSA rise.. Journal of Clinical Oncology, 2015, 33, 173-173.	1.6	0
168	A retrospective analysis of the effect of time from diagnosis to cystectomy on survival in patients with muscle-invasive bladder cancer receiving neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2015, 33, 360-360.	1.6	2
169	Preliminary evaluation of urinary soluble Met as a Biomarker for urothelial carcinoma of the bladder. Journal of Translational Medicine, 2014, 12, 199.	4.4	14
170	Reduced Glucocorticoid Receptor Expression Predicts Bladder Tumor Recurrence and Progression. American Journal of Clinical Pathology, 2014, 142, 157-164.	0.7	31
171	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 2014, 6, 224ra24.	12.4	3,665
172	Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. Modern Pathology, 2014, 27, 875-886.	5.5	136
173	Immunohistochemical expression of the mammalian target of rapamycin pathway in penile squamous cell carcinomas: a tissue microarray study of 112 cases. Histopathology, 2014, 64, 863-871.	2.9	23
174	Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer. Prostate, 2014, 74, 1308-1319.	2.3	24
175	Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network. Prostate, 2014, 74, 61-69.	2.3	16
176	Expression of UDP-glucuronosyltransferase 1A in bladder cancer: Association with prognosis and regulation by estrogen. Molecular Carcinogenesis, 2014, 53, 314-324.	2.7	41
177	VCL-ALK Renal Cell Carcinoma in Children With Sickle-cell Trait. American Journal of Surgical Pathology, 2014, 38, 858-863.	3.7	84
178	t(6;11) Renal Cell Carcinoma (RCC). American Journal of Surgical Pathology, 2014, 38, 604-614.	3.7	91
179	Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Human Pathology, 2014, 45, 1130-1138.	2.0	61
180	Insulin-like Growth Factor-1 Receptor Overexpression Is Associated With Outcome in Invasive Urothelial Carcinoma of Urinary Bladder: A Retrospective Study of Patients Treated Using Radical Cystectomy. Urology, 2014, 83, 1444.e1-1444.e6.	1.0	19

#	ARTICLE	IF	CITATIONS
181	Long Interspersed Element-1 Protein Expression Is a Hallmark of Many Human Cancers. <i>American Journal of Pathology</i> , 2014, 184, 1280-1286.	3.8	250
182	Sacrococcygeal teratomas: clinico-pathological characteristics and isochromosome 12p status. <i>Modern Pathology</i> , 2014, 27, 562-568.	5.5	19
183	A comprehensive resequence analysis of 250 kb region of 8q24.21 in men of African ancestry. <i>Prostate</i> , 2014, 74, 579-589.	2.3	20
184	ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder. <i>Human Pathology</i> , 2014, 45, 2233-2239.	2.0	24
185	Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 890-903.	7.0	275
186	The Utility of an Extensive Postchemotherapy Staging Evaluation in Patients Receiving Neoadjuvant Chemotherapy for Bladder Cancer. <i>Urology</i> , 2014, 84, 358-364.	1.0	14
187	Pathological characteristics and radiographic correlates of complex renal cysts. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1010-1016.	1.6	35
188	High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. <i>Journal of Hematology and Oncology</i> , 2014, 7, 47.	17.0	66
189	High Prevalence of Screen Detected Prostate Cancer in West Africans: Implications for Racial Disparity of Prostate Cancer. <i>Journal of Urology</i> , 2014, 192, 730-736.	0.4	46
190	Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms. <i>Human Pathology</i> , 2014, 45, 244-248.	2.0	22
191	GSTP1 Promoter Methylation is Associated with Recurrence in Early Stage Prostate Cancer. <i>Journal of Urology</i> , 2014, 192, 1542-1548.	0.4	48
192	Combining routine morphology, p16INK4a immunohistochemistry, and in situ hybridization for the detection of human papillomavirus infection in penile carcinomas: A tissue microarray study using classifier performance analyses. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 171-177.	1.6	32
193	Estrogen Receptor Alpha Prevents Bladder Cancer Development via INPP4B inhibited Akt Pathway <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2014, 5, 7917-7935.	1.8	63
194	Epigenetic inactivation of VGF associated with Urothelial Cell Carcinoma and its potential as a non-invasive biomarker using urine. <i>Oncotarget</i> , 2014, 5, 3350-3361.	1.8	17
195	An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUC) and its potential use for surveillance after transurethral resection using urine. <i>Oncotarget</i> , 2014, 5, 5218-5233.	1.8	19
196	Epidemiologic profile, sexual history, pathologic features, and human papillomavirus status of 103 patients with penile carcinoma. <i>World Journal of Urology</i> , 2013, 31, 861-867.	2.2	110
197	Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder. <i>Human Pathology</i> , 2013, 44, 612-622.	2.0	15
198	Molecular genetics and genomics progress in urothelial bladder cancer. <i>Seminars in Diagnostic Pathology</i> , 2013, 30, 313-320.	1.5	18

#	ARTICLE	IF	CITATIONS
199	<i>TERT</i> Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine. <i>Cancer Research</i> , 2013, 73, 7162-7167.	0.9	214
200	Frequent truncating mutations of STAG2 in bladder cancer. <i>Nature Genetics</i> , 2013, 45, 1428-1430.	21.4	164
201	Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas. <i>Human Pathology</i> , 2013, 44, 2323-2330.	2.0	16
202	<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6021-6026.	7.1	1,202
203	Molecular Pathology of Urinary Bladder Cancer. , 2013, , 229-253.		1
204	Immunohistochemical profile of the penile urethra and differential expression of GATA3 in urothelial versus squamous cell carcinomas of the penile urethra. <i>Human Pathology</i> , 2013, 44, 2760-2767.	2.0	22
205	Activation of Mammalian Target of Rapamycin Signaling Pathway Markers in Minute Adenocarcinoma of the Prostate. <i>Urology</i> , 2013, 82, 1083-1089.	1.0	2
206	High Levels of Phosphatase and Tensin Homolog Expression Are Associated With Tumor Progression, Tumor Recurrence, and Systemic Metastases in pT1 Urothelial Carcinoma of the Bladder: A Tissue Microarray Study of 156 Patients Treated by Transurethral Resection. <i>Urology</i> , 2013, 81, 116-122.	1.0	16
207	Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma. <i>Human Pathology</i> , 2013, 44, 2668-2676.	2.0	23
208	Focal positive prostate-specific membrane antigen (PSMA) expression in ganglionic tissues associated with prostate neurovascular bundle: Implications for novel intraoperative PSMA-based fluorescent imaging techniques. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 572-575.	1.6	10
209	The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases. <i>Human Pathology</i> , 2013, 44, 2690-2695.	2.0	42
210	Chromophobe Renal Cell Carcinoma: Multiphase MDCT Enhancement Patterns and Morphologic Features. <i>American Journal of Roentgenology</i> , 2013, 201, 1268-1276.	2.2	48
211	Clinical Applications of Recent Molecular Advances in Urologic Malignancies. <i>Advances in Anatomic Pathology</i> , 2013, 20, 175-203.	4.3	26
212	Renal Tumors. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1518-1531.	3.7	154
213	Utilization of a TFE3 Break-apart FISH Assay in a Renal Tumor Consultation Service. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1150-1163.	3.7	159
214	Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma. <i>Cell Cycle</i> , 2013, 12, 1058-1070.	2.6	36
215	Renal cell carcinoma presenting with brain metastasis from a 1.6 cm primary tumor. <i>Canadian Journal of Urology</i> , 2013, 20, 6965-7.	0.0	0
216	Emerging Critical Role of Molecular Testing in Diagnostic Genitourinary Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 372-390.	2.5	42

#	ARTICLE	IF	CITATIONS
217	Molecular Confirmation of t(6;11)(p21;q12) Renal Cell Carcinoma in Archival Paraffin-embedded Material Using a Break-apart TFE8 FISH Assay Expands its Clinicopathologic Spectrum. American Journal of Surgical Pathology, 2012, 36, 1516-1526.	3.7	112
218	Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 428-433.	1.6	51
219	High-Grade Prostatic Adenocarcinoma Present in a Single Biopsy Core is Associated With Increased Extraprostatic Extension, Seminal Vesicle Invasion, and Positive Surgical Margins at Prostatectomy. Urology, 2012, 79, 863-868.	1.0	9
220	A 66-Year-old Man With Prostate-specific Antigen Recurrence and Lung Mass After Radical Prostatectomy. Urology, 2012, 80, 247-249.	1.0	2
221	High-grade papillary urothelial carcinoma of the urinary tract: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center. Human Pathology, 2012, 43, 115-120.	2.0	20
222	Thyroid transcription factor 1 expression in a case of renal collecting duct carcinoma-Reply. Human Pathology, 2012, 43, 1154.	2.0	0
223	Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?. Nature Reviews Urology, 2012, 9, 41-51.	3.8	113
224	Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Modern Pathology, 2012, 25, 1543-1549.	5.5	124
225	GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor. Human Pathology, 2012, 43, 2033-2040.	2.0	67
226	Molecular Pathology of Bladder Cancer. Surgical Pathology Clinics, 2012, 5, 843-858.	1.7	3
227	Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU International, 2012, 109, 1716-1726.	2.5	187
228	ERG gene rearrangements are common in prostatic small cell carcinomas. Modern Pathology, 2011, 24, 820-828.	5.5	191
229	Immunohistology of the Prostate, Bladder, Kidney, and Testis. , 2011, , 593-661.		6
230	Prevalence of the Alternative Lengthening of Telomeres Telomere Maintenance Mechanism in Human Cancer Subtypes. American Journal of Pathology, 2011, 179, 1608-1615.	3.8	423
231	Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center. Human Pathology, 2011, 42, 1799-1803.	2.0	19
232	Interobserver Variability in Histologic Evaluation of Radical Prostatectomy Between Central and Local Pathologists: Findings of TAX 3501 Multinational Clinical Trial. Urology, 2011, 77, 1155-1160.	1.0	59
233	Immunohistochemical Analysis of SMARCB1/INI-1 Expression in Collecting Duct Carcinoma. Urology, 2011, 78, 474.e1-474.e5.	1.0	40
234	Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget, 2011, 2, 627-637.	1.8	383

#	ARTICLE	IF	CITATIONS
235	PAX2(âˆ“)/PAX8(âˆ“)/Inhibin A(+) Immunoprofile in Hemangioblastoma. American Journal of Surgical Pathology, 2011, 35, 262-267.	3.7	57
236	Diagnostic Use of PAX8, CAIX, TTF-1, and TGB in Metastatic Renal Cell Carcinoma of the Thyroid. American Journal of Surgical Pathology, 2011, 35, 757-761.	3.7	48
237	Should Intervening Benign Tissue Be Included in the Measurement of Discontinuous Foci of Cancer on Prostate Needle Biopsy? Correlation With Radical Prostatectomy Findings. American Journal of Surgical Pathology, 2011, 35, 1351-1355.	3.7	66
238	Immunoexpression Status and Prognostic Value of mTOR and Hypoxia-Induced Pathway Members in Primary and Metastatic Clear Cell Renal Cell Carcinomas. American Journal of Surgical Pathology, 2011, 35, 1549-1556.	3.7	73
239	Immunohistochemistry for ERG Expression as a Surrogate for TMPRSS2-ERG Fusion Detection in Prostatic Adenocarcinomas. American Journal of Surgical Pathology, 2011, 35, 1014-1020.	3.7	135
240	Distinctive Immunohistochemical Profile of Penile Intraepithelial Lesions. American Journal of Surgical Pathology, 2011, 35, 553-562.	3.7	69
241	High prevalence of polyclonal hypergammaglobulinemia in adult males in Ghana, Africa. American Journal of Hematology, 2011, 86, 554-558.	4.1	10
242	An EGFR-ERK-SOX9 Signaling Cascade Links Urothelial Development and Regeneration to Cancer. Cancer Research, 2011, 71, 3812-3821.	0.9	101
243	Increased gene copy number of ERG on chromosome 21 but not TMPRSS2â€“ERG fusion predicts outcome in prostatic adenocarcinomas. Modern Pathology, 2011, 24, 1511-1520.	5.5	57
244	PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients. Clinical Cancer Research, 2011, 17, 6563-6573.	7.0	309
245	Molecular Diagnostics in Urologic Malignancies: A Work in Progress. Archives of Pathology and Laboratory Medicine, 2011, 135, 610-621.	2.5	24
246	A Distinctive Subset of PEComas Harbors TFE3 Gene Fusions. American Journal of Surgical Pathology, 2010, 34, 1395-1406.	3.7	379
247	PAX8 (+)/p63 (âˆ“) Immunostaining Pattern in Renal Collecting Duct Carcinoma (CDC). American Journal of Surgical Pathology, 2010, 34, 965-969.	3.7	123
248	Xp11 Translocation Renal Cell Carcinoma (RCC): Extended Immunohistochemical Profile Emphasizing Novel RCC Markers. American Journal of Surgical Pathology, 2010, 34, 1295-1303.	3.7	181
249	Theranostic and prognostic biomarkers: genomic applications in urological malignancies. Pathology, 2010, 42, 384-394.	0.6	45
250	Nonâ€“invasive papillary urothelial neoplasms: The 2004 WHO/ISUP classification system. Pathology International, 2010, 60, 1-8.	1.3	140
251	Conventional prostatic adenocarcinoma arising in a multilocular prostatic cystadenoma. Pathology International, 2010, 60, 413-416.	1.3	7
252	Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer, 2010, 116, 5517-5526.	4.1	66

#	ARTICLE	IF	CITATIONS
253	<i>ERG</i> fusion as a marker of prostatic lineage in small cell carcinoma. <i>Histopathology</i> , 2010, 57, 633-633.	2.9	6
254	A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 3057-3066.	7.0	66
255	Decreased Expression of Cyr61 Is Associated with Prostate Cancer Recurrence after Surgical Treatment. <i>Clinical Cancer Research</i> , 2010, 16, 5908-5913.	7.0	23
256	The Relationship of Vascular Endothelial Growth Factor and Coagulation Factor (Fibrin and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622 To	1.0	35
257	Low-Grade Papillary Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic Analysis of a Post World Health Organization/International Society of Urological Pathology Classification Cohort From a Single Academic Center. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 1160-1163.	2.5	65
258	Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model. <i>Cancer Research</i> , 2009, 69, 4309-4318.	0.9	140
259	TMPRSS2- <i>ERG</i> gene fusions are infrequent in prostatic ductal adenocarcinomas. <i>Modern Pathology</i> , 2009, 22, 359-365.	5.5	51
260	TMPRSS2- <i>ERG</i> gene fusions are infrequent in prostatic ductal adenocarcinomas. <i>Modern Pathology</i> , 2009, 22, 1399-1400.	5.5	2
261	TMPRSS2- <i>ERG</i> gene fusion status in minute (minimal) prostatic adenocarcinoma. <i>Modern Pathology</i> , 2009, 22, 1415-1422.	5.5	48
262	PSMA expression in Schwannoma: A potential clinical mimicker of metastatic prostate carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 525-528.	1.6	47
263	Topoisomerase II Status in Renal Medullary Carcinoma: Immuno-Expression and Gene Copy Alterations of a Potential Target of Therapy. <i>Journal of Urology</i> , 2009, 182, 735-740.	0.4	38
264	Comparison of Gene Expression Profiles in Tubulocystic Carcinoma and Collecting Duct Carcinoma of the Kidney. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1103-1106.	3.7	67
265	Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia tissues. <i>Prostate</i> , 2008, 68, 766-772.	2.3	78
266	Profiling the expression pattern of GPI transamidase complex subunits in human cancer. <i>Modern Pathology</i> , 2008, 21, 979-991.	5.5	47
267	Benign Mimickers of Prostate Adenocarcinoma on Needle Biopsy and Transurethral Resection. <i>Surgical Pathology Clinics</i> , 2008, 1, 1-41.	1.7	9
268	Mesenchymal Tumors of the Prostate. <i>Surgical Pathology Clinics</i> , 2008, 1, 105-128.	1.7	3
269	Aggressive recurrent respiratory papillomatosis in a neonate. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2008, 72, 917-920.	1.0	16
270	Fat-Predominant Mixed Epithelial Stromal Tumor (MEST): Report of a Unique Case Mimicking Angiomyolipoma. <i>International Journal of Surgical Pathology</i> , 2008, 16, 73-77.	0.8	2

#	ARTICLE	IF	CITATIONS
271	Papillary Renal Cell Carcinoma With Low-grade Spindle Cell Foci. American Journal of Surgical Pathology, 2008, 32, 1353-1359.	3.7	64
272	Aberrant Diffuse Expression of p63 in Adenocarcinoma of the Prostate on Needle Biopsy and Radical Prostatectomy: Report of 21 Cases. American Journal of Surgical Pathology, 2008, 32, 461-467.	3.7	95
273	Distinguishing Prostatic From Colorectal Adenocarcinoma on Biopsy Samples: The Role of Morphology and Immunohistochemistry. Archives of Pathology and Laboratory Medicine, 2007, 131, 599-603.	2.5	37
274	Widespread High-grade Prostatic Intraepithelial Neoplasia on Prostatic Needle Biopsy: A Significant Likelihood of Subsequently Diagnosed Adenocarcinoma. American Journal of Surgical Pathology, 2006, 30, 1184-1188.	3.7	87
275	Radiofrequency thermal ablation of hepatocellular carcinoma before liver transplantation ? a clinical and histological examination. Clinical Transplantation, 2006, 20, 695-705.	1.6	53
276	Interobserver Agreement in Hepatitis C Grading and Staging and in the Banff Grading Schema for Acute Cellular Rejection: The "Hepatitis C" Multi-Institutional Trial Experience. Archives of Pathology and Laboratory Medicine, 2006, 130, 1157-1162.	2.5	23
277	Diagnostic Molecular Pathology: An Increasingly Indispensable Tool for the Practicing Pathologist. Archives of Pathology and Laboratory Medicine, 2006, 130, 1339-1348.	2.5	10
278	Cadaveric Orthotopic Auxiliary Split Liver Transplantation and Kidney Transplantation: An Alternative for Type 1 Primary Hyperoxaluria. Transplantation, 2005, 80, 421-424.	1.0	21
279	Pretransplant MELD Score As a Predictor of Outcome After Liver Transplantation for Chronic Hepatitis C. American Journal of Transplantation, 2003, 3, 626-630.	4.7	61
280	The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation, 2003, 76, 1583-1588.	1.0	101
281	Diagnostic Molecular Pathology: Current Techniques and Clinical Applications, Part I. Baylor University Medical Center Proceedings, 2003, 16, 379-383.	0.5	21
282	Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders ¹ . Transplantation, 2002, 74, 1090-1095.	1.0	82
283	Malabsorption Due to Cholecystokinin Deficiency in a Patient with Autoimmune Polyglandular Syndrome Type I. New England Journal of Medicine, 2001, 344, 270-274.	27.0	82
284	Detection of low level benzene exposure in supermarket wrappers by urinary muconic acid. Biomarkers, 1999, 4, 106-117.	1.9	16
285	Protection by Cyclosporine A against Normothermic Liver Ischemia-Reperfusion in Pigs. Journal of Surgical Research, 1998, 75, 116-126.	1.6	19
286	RECURRENT PRIMARY SCLEROSING CHOLANGITIS AFTER ORTHOTOPIC LIVER TRANSPLANTATION. Transplantation, 1998, 66, 1300-1306.	1.0	133